A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty

Journal of Clinical Epidemiology

Volumn 67, Issue 10, 2014, Pages 1172-1177

  Cortés, Jordi ^a   González, José A ^a   Campbell, Michael J ^b   Cobo, Erik ^a  

^a UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cancer; Clinical trial; Concordance; Hazard ratio; Median ratio; Survival

Indexed keywords

ARTICLE; CALCULATION; CANCER SURVIVAL; HAZARD RATIO; MEDIAN RATIO; SAMPLE SIZE; STATISTICAL PARAMETERS; SURVIVAL TIME; CONFIDENCE INTERVAL; HUMAN; MORTALITY; NEOPLASM; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

CONFIDENCE INTERVALS; HUMANS; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84908257157     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2014.05.017     Document Type: Article

References (21)

1. E.W. Lau, and G.A. Ng Visual illusions created by survival curves and the need to avoid potential misinterpretation Med Decis Making 22 2002 238 244
2. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
3. D.G. Kleinbaum, and M. Klein Survival analysis: a self-learning approach 2nd ed. 2005 Springer New York, NY
4. S.L. Spruance, J.E. Reid, M. Grace, and M. Samore Hazard ratio in clinical trials Antimicrob Agents Chemother 48 2004 2782 2792
5. M. Hernán The hazards of hazard ratios Epidemiology 21 2010 13 15
6. L.D. Case, G. Kimmick, E.D. Pasketta, K. Lohmana, and R. Tuckerb Interpreting measures of treatment effect in cancer clinical trials Oncologist 7 2002 181 187
7. L.M. Schwartz, S. Woloshin, E.L. Dvorin, and H.G. Welch Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks BMJ 333 2006 1248
8. K.J. Carroll On the use and utility of the Weibull model in the analysis of survival data Control Clin Trials 24 2003 682 701
9. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Siebels Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
10. D. Machin, M.J. Campbell, S.B. Tan, and S.H. Tan Sample size tables for clinical studies 3rd ed. 2008 Wiley-Blackwell Chichester, UK
11. T.S. King, and V.M. Chinchilli Robust estimators of the concordance correlation coefficient J Biopharm Stat 11 2001 83 105
12. J.M. Bland, and D.G. Altman Statistical methods for assessing agreement between two methods of clinical measurement Lancet 1 1986 307 310
13. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O'Callaghan, D. Tu, and N.C. Tebbutt K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
14. P.J. Goodwin, M. Leszcz, M. Ennis, J. Koopmans, L. Vincent, and H. Guther The effect of group psychosocial support on survival in metastatic breast cancer N Engl J Med 345 2001 1719 1726
15. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
16. D.J. Jonker, C.J. O'Callaghan, C.S. Karapetis, J.R. Zalcberg, D. Tu, and H.J. Au Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048
17. B. Löwenberg, G.J. Ossenkoppele, W. van Putten, H.C. Schouten, C. Graux, and A. Ferrant High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med 361 2009 1235 1248
18. S. Michiels, P. Piedbois, S. Burdett, N. Syz, L. Stewart, and J.P. Pignon Meta-analysis when only the median survival times are known: a comparison with individual patient results Int J Technol Assess Health Care 21 2005 119 125
19. D.G. Altman, B.L. De Stavola, S.B. Love, and K.A. Stepniewska Review of survival analyses published in cancer journals Br J Cancer 72 1995 511 518
20. S. Saha, S. Saint, and D.A. Christakis Impact factor: a valid measure of journal quality? J Med Libr Assoc 91 2003 41 46
21. D. Moher, S. Hopewell, K.F. Schulz, V. Montori, P.C. Gøtzsche, and P.J. Devereaux CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trial BMJ 340 2010 c869